Vaccine & Diagnostics
Roslin Technologies is developing a pipeline of animal health products incorporating vaccines and diagnostics.
Escherichia coli is a human pathogen that can cause severe gastrointestinal disease that is potentially fatal.
An Escherichia coli O157 vaccine comprising three bacterial antigens has been jointly developed at Roslin Institute and Moredun Research Institute. It is intended for use in cattle to reduce bacterial colonisation and shedding in faeces. This will ultimately benefit human health through reduced contamination of food stuffs with enterohemorrhagic E. coli which causes hemorrhagic colitis and hemolytic uraemic syndrome in people.
Roslin Technologies has taken an exclusive license for this vaccine. As a first step to commercialization, the project aims to confirm efficacy in field conditions on a US feedlot.